Cargando…

Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review

BACKGROUND: Recent studies suggest certain antiretroviral therapy (ART) drugs are associated with increases in cardiovascular disease. PURPOSE: We performed a systematic review and meta-analysis to summarize the available evidence, with the goal of elucidating whether specific ART drugs are associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bavinger, Clay, Bendavid, Eran, Niehaus, Katherine, Olshen, Richard A., Olkin, Ingram, Sundaram, Vandana, Wein, Nicole, Holodniy, Mark, Hou, Nanjiang, Owens, Douglas K., Desai, Manisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608726/
https://www.ncbi.nlm.nih.gov/pubmed/23555704
http://dx.doi.org/10.1371/journal.pone.0059551
_version_ 1782264272300015616
author Bavinger, Clay
Bendavid, Eran
Niehaus, Katherine
Olshen, Richard A.
Olkin, Ingram
Sundaram, Vandana
Wein, Nicole
Holodniy, Mark
Hou, Nanjiang
Owens, Douglas K.
Desai, Manisha
author_facet Bavinger, Clay
Bendavid, Eran
Niehaus, Katherine
Olshen, Richard A.
Olkin, Ingram
Sundaram, Vandana
Wein, Nicole
Holodniy, Mark
Hou, Nanjiang
Owens, Douglas K.
Desai, Manisha
author_sort Bavinger, Clay
collection PubMed
description BACKGROUND: Recent studies suggest certain antiretroviral therapy (ART) drugs are associated with increases in cardiovascular disease. PURPOSE: We performed a systematic review and meta-analysis to summarize the available evidence, with the goal of elucidating whether specific ART drugs are associated with an increased risk of myocardial infarction (MI). DATA SOURCES: We searched Medline, Web of Science, the Cochrane Library, and abstract archives from the Conference on Retroviruses and Opportunistic Infections and International AIDS Society up to June 2011 to identify published articles and abstracts. STUDY SELECTION: Eligible studies were comparative and included MI, strokes, or other cardiovascular events as outcomes. DATA EXTRACTION: Eligibility screening, data extraction, and quality assessment were performed independently by two investigators. DATA SYNTHESIS: Random effects methods and Fisher’s combined probability test were used to summarize evidence. FINDINGS: Twenty-seven studies met inclusion criteria, with 8 contributing to a formal meta-analysis. Findings based on two observational studies indicated an increase in risk of MI for patients recently exposed (usually defined as within last 6 months) to abacavir (RR 1.92, 95% CI 1.51–2.42) and protease inhibitors (PI) (RR 2.13, 95% CI 1.06–4.28). Our analysis also suggested an increased risk associated with each additional year of exposure to indinavir (RR 1.11, 95% CI 1.05–1.17) and lopinavir (RR 1.22, 95% CI 1.01–1.47). Our findings of increased cardiovascular risk from abacavir and PIs were in contrast to four published meta-analyses based on secondary analyses of randomized controlled trials, which found no increased risk from cardiovascular disease. CONCLUSION: Although observational studies implicated specific drugs, the evidence is mixed. Further, meta-analyses of randomized trials did not find increased risk from abacavir and PIs. Our findings that implicate specific ARTs in the observational setting provide sufficient evidence to warrant further investigation of this relationship in studies designed for that purpose.
format Online
Article
Text
id pubmed-3608726
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36087262013-04-03 Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review Bavinger, Clay Bendavid, Eran Niehaus, Katherine Olshen, Richard A. Olkin, Ingram Sundaram, Vandana Wein, Nicole Holodniy, Mark Hou, Nanjiang Owens, Douglas K. Desai, Manisha PLoS One Research Article BACKGROUND: Recent studies suggest certain antiretroviral therapy (ART) drugs are associated with increases in cardiovascular disease. PURPOSE: We performed a systematic review and meta-analysis to summarize the available evidence, with the goal of elucidating whether specific ART drugs are associated with an increased risk of myocardial infarction (MI). DATA SOURCES: We searched Medline, Web of Science, the Cochrane Library, and abstract archives from the Conference on Retroviruses and Opportunistic Infections and International AIDS Society up to June 2011 to identify published articles and abstracts. STUDY SELECTION: Eligible studies were comparative and included MI, strokes, or other cardiovascular events as outcomes. DATA EXTRACTION: Eligibility screening, data extraction, and quality assessment were performed independently by two investigators. DATA SYNTHESIS: Random effects methods and Fisher’s combined probability test were used to summarize evidence. FINDINGS: Twenty-seven studies met inclusion criteria, with 8 contributing to a formal meta-analysis. Findings based on two observational studies indicated an increase in risk of MI for patients recently exposed (usually defined as within last 6 months) to abacavir (RR 1.92, 95% CI 1.51–2.42) and protease inhibitors (PI) (RR 2.13, 95% CI 1.06–4.28). Our analysis also suggested an increased risk associated with each additional year of exposure to indinavir (RR 1.11, 95% CI 1.05–1.17) and lopinavir (RR 1.22, 95% CI 1.01–1.47). Our findings of increased cardiovascular risk from abacavir and PIs were in contrast to four published meta-analyses based on secondary analyses of randomized controlled trials, which found no increased risk from cardiovascular disease. CONCLUSION: Although observational studies implicated specific drugs, the evidence is mixed. Further, meta-analyses of randomized trials did not find increased risk from abacavir and PIs. Our findings that implicate specific ARTs in the observational setting provide sufficient evidence to warrant further investigation of this relationship in studies designed for that purpose. Public Library of Science 2013-03-26 /pmc/articles/PMC3608726/ /pubmed/23555704 http://dx.doi.org/10.1371/journal.pone.0059551 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Bavinger, Clay
Bendavid, Eran
Niehaus, Katherine
Olshen, Richard A.
Olkin, Ingram
Sundaram, Vandana
Wein, Nicole
Holodniy, Mark
Hou, Nanjiang
Owens, Douglas K.
Desai, Manisha
Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review
title Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review
title_full Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review
title_fullStr Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review
title_full_unstemmed Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review
title_short Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review
title_sort risk of cardiovascular disease from antiretroviral therapy for hiv: a systematic review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608726/
https://www.ncbi.nlm.nih.gov/pubmed/23555704
http://dx.doi.org/10.1371/journal.pone.0059551
work_keys_str_mv AT bavingerclay riskofcardiovasculardiseasefromantiretroviraltherapyforhivasystematicreview
AT bendavideran riskofcardiovasculardiseasefromantiretroviraltherapyforhivasystematicreview
AT niehauskatherine riskofcardiovasculardiseasefromantiretroviraltherapyforhivasystematicreview
AT olshenricharda riskofcardiovasculardiseasefromantiretroviraltherapyforhivasystematicreview
AT olkiningram riskofcardiovasculardiseasefromantiretroviraltherapyforhivasystematicreview
AT sundaramvandana riskofcardiovasculardiseasefromantiretroviraltherapyforhivasystematicreview
AT weinnicole riskofcardiovasculardiseasefromantiretroviraltherapyforhivasystematicreview
AT holodniymark riskofcardiovasculardiseasefromantiretroviraltherapyforhivasystematicreview
AT hounanjiang riskofcardiovasculardiseasefromantiretroviraltherapyforhivasystematicreview
AT owensdouglask riskofcardiovasculardiseasefromantiretroviraltherapyforhivasystematicreview
AT desaimanisha riskofcardiovasculardiseasefromantiretroviraltherapyforhivasystematicreview